[Experimental studies on the mechanism of thrombocyte aggregation inhibition caused by sulfonylurea compounds. 2. Modification of blood sugar and thrombocyte aggregation by oral antidiabetics].
D000249:Adenosine Monophosphate / Q000037:antagonists & inhibitors; D000284:Administration, Oral; D000818:Animals; D001645:Biguanides / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism*; D002271:Carbutamide / Q000494:pharmacology; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D005905:Glyburide / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007275:Injections, Intravenous; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D012663:Semicarbazides / Q000494:pharmacology; D013453:Sulfonylurea Compounds / Q000494:pharmacology*; D014042:Tolazamide / Q000494:pharmacology; D014044:Tolbutamide / Q000494:pharmacology
D001645:Biguanides; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D011743:Pyrimidines; D012663:Semicarbazides; D013453:Sulfonylurea Compounds; D000249:Adenosine Monophosphate; D014044:Tolbutamide; D014042:Tolazamide; D002271:Carbutamide; D005905:Glyburide
Experimentelle Untersuchungen zum Mechanismus der durch Sulfonylharnstoffe verursachten Hemmung der Thrombozytenaggregation